Skip to main content

Scientific Resources

Go4Life – Maintaining good health and function

Chhanda DUTTA, Chief, Clinical Gerontology Branch, Division of Geriatrics and Clinical Gerontology (DGCG)

This month, NIA is celebrating our second annual Go4Life Month. As part of that celebration, we’re reaching out to our Go4Life® partners and the research community to help us find ways to encourage older people to exercise and lead healthy, active lives. This year’s theme is “Fit4Function.” So what is Fit4Function all about, anyway?

Reproducibility: Another bureaucratic speed bump?

John WILLIAMS, Health Scientist Administrator, Division of Aging Biology (DAB)

So you thought your science was already rigorous and reproducible…

Last fall, NIH released new guidelines for implementing rigor and transparency in research project grants. Applications for research grants and mentored career development awards submitted in 2016 must include information on scientific rigor and reproducibility. What’s going on?

Connect with NIA at AGS!

Marie BERNARD, Deputy Director, Office of the Director (OD)

California, here we come! No, we’re not participating in a gold rush, we’re going to the annual meeting of the American Geriatrics Society (AGS) next week in Long Beach. We’re looking forward to seeing old friends and making new ones. We also hope that you’ll take the opportunity to connect with NIA staff at the meeting, during scientific sessions and at the Exhibit Hall.

The Clinical Trials Advisory Panel: A good start for a clinical trial

Sergei ROMASHKAN, , Division of Geriatrics and Clinical Gerontology (DGCG)

Large-scale clinical trials are expensive. They require a lot of time and money on the part of the investigators. So does preparing an NIH application for a clinical trial. One way you can save time and money at the beginning of the process is to submit a concept proposal for your trial to NIA’s Clinical Trials Advisory Panel (CTAP).

Data sharing: The name of the game in Alzheimer’s research

, ,

Thousands of gene candidates in the human genome have the potential to play a role in the onset and progression of Alzheimer’s disease. But you are just one scientist. How can you even start such an enormous task? This quest—one scientist analyzing thousands of gene candidates—can seem overwhelming. I want to share with you two great NIA-funded resources that collect and store biological specimens and data—and are available to you and the wider research community.

Oldies but goodies from 2015

, ,

The big news of 2016 so far is the increase in the NIA budget. We’re very excited about the many opportunities in aging research that will be possible because of these extra funds. As we flesh out new funding opportunities and wait for applications in response to existing announcements, we thought we would reprise a few interesting posts from the last few months in case you missed them. If you missed a few, now is your chance to catch up.

A second geroscience summit

Felipe SIERRA, Director, Division of Aging Biology (DAB)

I’m very pleased to announce that the Trans-NIH GeroScience Interest Group (GSIG) and partners will host its second summit in 2016. The “Disease Drivers of Aging: 2016 Advances in Geroscience Summit” will take place on April 13–14 at the New York Academy of Sciences in New York City. Members of the Geroscience Interest Group from the NIH, with essential collaboration and support from the New York Academy of Sciences, the American Federation for Aging Research, and the Gerontological Society of America, have developed a theme and program for a second geroscience summit requested by the research community.

The rise and fall and rise of early-stage investigators – The story continues

Robin BARR, Director, DEA, Division of Extramural Activities (DEA)

Those of you who read part 1 of this post a couple of weeks ago will remember that I raised a question at the end of that post: Could a policy affecting all investigators (the NIH policy change to allow a single amended submission) have a singular effect on a sub-group of investigators—early-stage and other inexperienced researchers? This week, we have the answer!